Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2004 December; 5(4): 92–100.
Published online 2004 September 13. doi:  10.1208/pt050463
PMCID: PMC2750488

Effect of organogel components on in vitro nasal delivery of propranolol hydrochloride


The purpose of this research was to evaluate in vitro transnasal sustained-release ability of sorbitan monostearate (SMS) organogels in isopropyl myristate (IM). Organogels were prepared containing SMS (2.5%–20%) and water (5%–25%) in IM and analyzed microscopically for phase behavior. The effect of Tween surfactants on gel strength and in vitro nasal diffusion of propranolol is reported. The in vitro nasal release retardant effect of SMS and Tween 20 was investigated using factorial design. The microscopic changes in structure of organogel during in vitro nasal diffusion were studied. The water-holding capacity of SMS organogels in IM increased with SMS concentration. The release retardant effect with incorportation of cosurfactant was of the order of Tween 80> Tween 60> Tween 20. Gel strengthening and increased viscosity were evident with increased concentration of SMS and Tween 20. The 3-dimensional network of SMS molecules controls the diffusional drug release. The organogel system on nasal mucosa during diffusion is dynamic in nature and changes continuously with the time of diffusion. The water penetration in the organogel network results in percolation and emulsification of organogel, thus affecting the release. Organogels provided an effective barrier for diffusion of propranolol. The surface epithelium lining and the granular cellular structure of treated nasal mucosa were intact.

Keywords: sorbitan monostearate, organogel, nasal, propranolol, in vitro, retard release

Full Text

The Full Text of this article is available as a PDF (1018K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Hussain A, Kimura R, Huang CH, Mustafa R. Nasal absorption of ergotamine tartrate in rats. Int J Pharm. 1984;21:289–293. doi: 10.1016/0378-5173(84)90187-X. [Cross Ref]
2. Pontiroli A. Intranasal calcitonin and plasma calcium concentration in normal subjects. BMJ. 1985;290:1390–1395. doi: 10.1136/bmj.290.6479.1390. [PMC free article] [PubMed] [Cross Ref]
3. Merkus FWHM, inventor. Nasal melatonin composition. US patent 6 007 834. March 26, 1998.
4. Nishimoto Y, Naoki N. Powder dosage form of insulin for nasal administration. J Control Release. 1984;1:15–24. doi: 10.1016/0168-3659(84)90017-8. [Cross Ref]
5. Illum L, Critchley H, Davis SS. Nasal administration of gentamicin using novel microsphere delivery system. Int J Pharm. 1988;46:261–265. doi: 10.1016/0378-5173(88)90087-7. [Cross Ref]
6. Farraj NF, Johansen BR, Davis SS, Illum L. Nasal administration of insulin using bioadhesive microspheres as a delivery system. J Control Release. 1990;3:253–261. doi: 10.1016/0168-3659(90)90016-M. [Cross Ref]
7. Hussain AA, Foster T, Hirai S. Nasal absorption of propranolol in humans. J Pharm Sci. 1980;69:1240–1244. [PubMed]
8. Ahn BN, Kim SK, Shim CK. Proliposomes as an intranasal dosage form for the sustained delivery of propranolol. J Control Release. 1995;4:203–210. doi: 10.1016/0168-3659(94)00114-A. [Cross Ref]
9. Vyas SP, Talwar N, Jain NK. An erythrocyte based bioadhesive system for nasal delivery of propranolol. J Control Release. 1993;23:231–237. doi: 10.1016/0168-3659(93)90004-O. [Cross Ref]
10. Tan YTF, Peh KK, Al-Hanbali O. Effect of carbopol and polyvinylpyrrolidone on the mechanical, rheological, and release properties of bioadhesive polyethylene glycol gels. AAPS PharmSciTech. 2000;1:E24–E24. doi: 10.1208/pt010324. [PMC free article] [PubMed] [Cross Ref]
11. D'Cruz OJ, Yiv SH, Uckun FM. GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion. AAPS PharmSciTech. 2001;2:E5–E5. doi: 10.1208/pt020205. [PMC free article] [PubMed] [Cross Ref]
12. Pisal SS, Paradkar AR, Mahadik KR, Kadam SS. Pluronic gels for nasal delivery of vitamin B12. Part I: Preformulation study. Int J Pharm. 2004;270:37–45. doi: 10.1016/j.ijpharm.2003.10.005. [PubMed] [Cross Ref]
13. Pisal SS, Reddy P, Ketkar AR, Patil VB, Paradkar AR. Transnasal absorption of melatonin from thermo-reversible gels of pluronic PF 127 gels. Paper presented at: 62nd World Pharmaceutical Congress; September 3, 2002, Nice, France; DDT-P-039.
14. Anand B, Pisal SS, Paradkar AR, Mahadik KR. Applications of organogels in pharmaceuticals. J Sci Ind Res (India). 2001;60:311–318.
15. Lin Y, Kachar B, Weiss RG. Novel family of gelators of organic fluids and the structure of their gels. J Am Chem Soc. 1989;111:5542–5551. doi: 10.1021/ja00197a005. [Cross Ref]
16. Shilpa K, Rees GD, Lawrence MJ. Formation of electrically conducting microemulusion based organogels. Int J Pharm. 2003;250:65–83. doi: 10.1016/S0378-5173(02)00491-X. [PubMed] [Cross Ref]
17. Willimann H, Walde P. Lecithin organogels as matrix for transdermal transport of drugs. J Pharm Sci. 1992;81:871–874. doi: 10.1002/jps.2600810906. [PubMed] [Cross Ref]
18. Dreher F, Walde P, Walther P, Wehrli E. Interaction of lecithin microemulsion gel with human stratum corneum and its effect on transdermal transport. J Control Release. 1997;45:131–140. doi: 10.1016/S0168-3659(96)01559-3. [Cross Ref]
19. Fresta M, Puglisi G, Ventura CA, Panico AM. Lecithin organogels as potential ophthalmic drug delivery systems: a toxicology study. J Control Release. 1997;48:328–329.
20. Florence AT, Murdan S, Bergh BVD, Gregoriadis G. Water-in-sorbitan monostearate organogels (water in oil gels) J Pharm Sci. 1999;88:615–619. doi: 10.1021/js980343j. [PubMed] [Cross Ref]
21. Murdan S, Gregoriadis G, Florence AT. Novel sorbitan monostearate organogels. J Pharm Sci. 1999;88:608–614. doi: 10.1021/js980342r. [PubMed] [Cross Ref]
22. Choi HG. Effect of sodium chloride on gelation temperature, gel strength and bioadhesive force of poloxamer gels containing diclofenac sodium. Int J Pharm. 2001;226:195–205. doi: 10.1016/S0378-5173(01)00809-2. [PubMed] [Cross Ref]
23. Pisal SS, Reddy P, Mahadik KR, Kadam SS. Nasal melatonin gels using pluronic-PF-127 for chronobiological treatment of sleep disorder.Ind J Biotech. In press.
24. Goto S, Kawata M, Suzuki T, Kim NS. Preparation and evaluation of Eudragit gel. I. Eudragit organogel contining drug and rectal sustained release preparation. J Pharm Sci. 1991;80:958–961. doi: 10.1002/jps.2600801011. [PubMed] [Cross Ref]
25. Shilpa K, Rees GD, Lawrence MJ. Gelatin stabilized microemulsionbased organogels: rheology and its application in iontophoretic transdermal drug delivery. J Control Release. 1999;60:355–365. doi: 10.1016/S0168-3659(99)00092-9. [PubMed] [Cross Ref]
26. Murdan S, Gregoriadis G, Florence AT. Non-ionic surfactant organogels incorporating niosomes. STP Pharma Sci. 2004;6:44–48.
27. Murdan S, Gregoriadis G, Florence AT. Interaction of nonionic surfactant based organogel with aqueous media. Int J Pharm. 1999;180:211–214. doi: 10.1016/S0378-5173(99)00007-1. [PubMed] [Cross Ref]
28. Kibbe HA. Handbook of Pharmaceutical Excipients. London, UK: American Pharmaceutical Association, Pharmaceutical Press; 2000.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists